Table 1.

A summary of the lncRNA related to resistance of cancer.

LncRNA	Type of cancer	Type of drug	Drug	Factors	Signaling pathway	Reference
PVT1	GC	DNA-targeted drugs	Cisplatin	MRP1	Apoptosis, mTOR/HIF-1α/P-gp	Zhang et al.58
	OC	DNA-targeted drugs	Cisplatin or carboplatin-Docetaxel	TGF-beta 1, p-Smad4, Caspase-3	Apoptosis	Liu et al.80; Worku et al.81
HOTAIR	OC	DNA-targeted drugs	Cisplatin	XAV939	Apoptosis, Wnt/β-catenin	Li et al.82
	NSCLC	DNA-targeted drugs	Cisplatin	Klf4, Iκ-Bα	NF-κB, CSC	Ozes et al.83; Janssens et al.84; Liu et al.85
	OC	DNA-targeted drugs	Carboplatin	–	DNA methylation	Wu et al.86
	BC	Antihormone therapy	Tamoxifen	–	ER-mediated transcription inhibition	Xue et al.87
	AL	Tyrosine kinase inhibitors	imatinib	PI3K, Akt	Apoptosis, PI3K/Akt	Cruz-Miranda et al.88; Wang et al.89
AK022798	GC	DNA-targeted drugs	Cisplatin	MRP1 and P-gp	–	Hang et al.90
UCA1	Bladder cancer	DNA-targeted drugs	Cisplatin	srpk1	Wnt, apoptosis,	Fan et al.91; Wang et al.92
	NSCLC	Tyrosine kinase inhibitors	Gefitinib	–	–	Cheng et al.93
	CRC	Antimetabolite therapy	5-FU	miR-204-5p	Apoptosis	Luo et al.94
	BC	Antihormone therapy	Tamoxifen	–	Wnt/β-catenin	Liu et al.95
	CML	Tyrosine kinase inhibitors	imatinib	MDR1, miR-16	MDR1/miR-16	Xiao et al.96
H19	OC	DNA-targeted drugs	Cisplatin	MEG3, miR-214	Nrf2	Wang et al.61; Zhan et al.97
	CRC	Antimetabolite therapy	Methotrexate	–	WNT/β-catenin	Luo et al.94
ANRIL	GC	DNA-targeted drugs	cisplatin	–	–	Lan et al.98
	GC	Antimetabolite therapy	Cisplatin and 5-FU	–	Apoptosis	Lan et al.98
	LAD	Cytotoxic drugs	Paclitaxel	cleaved-PARP, Bcl-2	Apoptosis	Xu et al.99
ROR	NSCLC	DNA-targeted drugs	Cisplatin	–	PI3K/Akt/mTOR	Shi et al.100
Zinc	OC	DNA-targeted drugs	Cisplatin	miRNA-150-5p, SP1	–	Xia et al.101
LINC00161	osteosarcoma	DNA-targeted drugs	Cisplatin	miR-645, IFIT2	Apoptosis	Wang et al.102
ENST00000457645	OC	DNA-targeted drugs	Cisplatin	–	Apoptosis	Yan et al.62
BLACAT1	GC	DNA-targeted drugs	Oxaliplatin	miR-361, ABCB1	–	Wu et al.103
MALAT-1	Pancreatic cancer	DNA-targeted drugs	Gemcitabine	miR-200c, miR-145, Sox2	CSC	Jiao et al.104
UCA1	GC	Cytotoxic drugs	Adriamycin	PARP, Bcl-2	Apoptosis	Shang et al.105
TUG1	BUC	Cytotoxic drugs	adriamycin	–	Wnt/β-catenin	Xie et al.106
HANR	HCC	Cytotoxic drugs	adriamycin	GSK3β	GSK3β	Xiao et al.107
ENST00000500843	LAD	Cytotoxic drugs	Paclitaxel	–	Apoptosis	Tian et al.108
NEAT1	PC	Cytotoxic drugs	Docetaxel	miR-34a	–	Tian et al.109
lnc-ATB	BC	Tyrosine kinase inhibitors	Trastuzumab	ZEB1, ZNF-217, miR-200c	TGF-β	Gajria et al.110
GAS5	BC	Tyrosine kinase inhibitors	Trastuzumab	mTOR, PTEN	mTOR	Li et al.111
BC087858	NSCLC	Tyrosine kinase inhibitors	Gefitinib	–	PI3K/AKT, MEK/ERK	Pan et al.112
SNHG5	LAD	Tyrosine kinase inhibitors	Gefitinib	miR-377	–	Wang et al.113
linc-VLDLR	HCC	Tyrosine kinase inhibitors	Sorafenib	ABC-G2	EVs	Takahashi et al.114
ARSR	RCC	Tyrosine kinase inhibitors	Sunitinib	AXL, c-MET, miR-34/miR-449	–	Qu et al.115
LINC00152	CRC	Antimetabolite therapy	5-FU	miR-139-5p	Apoptosis	Bian et al.116
LUCAT1	osteosarcoma	Antimetabolite therapy	Methotrexate	ABCB1, miR-200c	–	Han and Shi117
BCAR4	BC	Antihormone therapy	Tamoxifen	ERBB2, ERBB3, AKT	ERBB, apoptosis	van Agthoven et al.118
FENDRR	CML	Cytotoxic drugs	adriamycin	MDR1	Apoptosis	Zhang et al.119

BC, breast cancer; BUC, bladder urothelial carcinoma; CML, chronic myeloid leukemia; CRC, colorectal cancer; CSC, cancer stem cells; 5-FU, 5-fluorouracil; GC, gastric cancer; HCC, hepatocellular carcinoma; LAD, lung adenocarcinoma; lncRNA, long noncoding RNA; NFκB, nuclear factor κB’; NSCLC, non-small cell lung cancer; OC, ovarian cancer; PC, prostate cancer; RCC, renal cell carcinoma; TGF-β, transforming growth factor beta.